BioPharma Resources

Drug Trial Radar · NCT07412236

A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase IIIc Clinical Study Evaluating the Long-term Treatment of Hepatic Fibrosis in Chronic Hepatitis B With Hydronidone Capsules.

Last checked: Nov 19, 2026Latest source record: Nov 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 1,208 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

1,208

Planned (sponsor's estimate)

Start

Mar 23, 2026

Primary completion

Dec 30, 2028

Study completion Dec 30, 2028

Sponsor

Sponsor type
Industry
Collaborators
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
First posted
Feb 17, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is conducted as a randomized, double-blind, placebo-controlled, multicenter clinical trial on a background of entecavir therapy. It aims to evaluate the clinical benefits of Hydronidone Capsules in patients with liver fibrosis due to chronic hepatitis B. The study consists of a Screening/Baseline Period (4 weeks) and a Dosing/Observation Period (planned duration of 5 years, including a 52-week primary treatment phase and a 208-week long-term treatment phase).

Conditions

  • Liver Fibrosis
  • Liver Fibrosis in Chronic Hepatitis B

Interventions

  • Hydronidone (270mg)Drug

    Dosage: 30 mg/capsule, three capsules taken three times daily, resulting in a total daily therapeutic dose of 270 mg. The medication is administered orally half an hour before meals.

  • Hydronidone (Placebo Group)Drug

    Dosage: three capsules taken three times daily.The medication is administered orally half an hour before meals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Clinical Endpoint EventsTime frame: From the first dose administration to the end of the treatment period (Week 261).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.